进展期结直肠癌患者亚甲基四氢叶酸还原酶基因多态性与卡培他滨耐药及毒性反应的关系

The relationship between MTHFR polymorphism and capecitabine resistance and toxicity reaction in advanced colorectal cancer

目的检测进展期结直肠癌组织中MTHFR基因的表达,分析其与卡培他滨耐药及毒性反应的关系。方法 56例进展期结直肠癌患者的病理组织,检测MTHFRC677T位点的基因多态性,测试进展期结直肠癌患者原代肿瘤细胞对卡培他滨的响应。结果 MTHFRC677T位点TT型对卡培他滨化疗的敏感例数及化疗毒性反应例数均高于CC及CT型,且化疗毒性反应例数均高于CC基因型,差异均有统计学意义(P<0.05)。结论进展期结直肠癌化疗前应检测MTHFR基因多态性,MTHFRC677T基因TT型患者首选卡培他滨,化疗期间注意毒性反应的发生。

Objective To detect methylenetetrahydrofolate reductase （MTHFR） gene expression in advanced colorectal cancer tissue, and analyze its association with capecitabine resistance and toxicity reaction. Methods We collected 56 cancer tissue samples from patients with advanced colorectal cancer. We detected the polymorphism at MTHFRC677T loci and measured the response of colorectal primary tumor cells to capecitabine. Results The incidence of sensitivity to and chemotherapy toxicity reaction to capecitabin in TT genotype was higher than those in CC genotype and CT genotype at MTHFRC677T loci （P 〈 0.05）. Conclusion MTHFR gene polymorphism has to be detected before chemotherapy for patients with advanced colorectal cancer. The capecitabine is the pre- ferred drug for patients with TT genotype of MTHFR gene. The toxic reaction should be paid attention during period of chemotherapy.